ArticleDiscover oncology2025
Oesophageal metastasis of prostate cancer: a case report.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundOesophageal cancer is the seventh leading cause of cancer mortality worldwide. Prostate cancer metastasis to the oesophagus is exceedingly rare. We report an 82-year-old male patient. He presented to the gastroenterology clinic complaining of increased bowel movement frequency from baseline. The patient had a previous history of prostate cancer. Tumour marker analysis revealed markedly elevated levels of carcinoembryonic antigen (CEA), carbohydrate antigen 19 - 9 (CA19-9), and prostate-specific antigen (PSA). Contrast-enhanced magnetic resonance imaging (MRI) of the upper abdomen suggested multiple retroperitoneal lymph node metastases and metastatic lesions in several lumbar vertebrae. Colonoscopy revealed inflammatory changes in the colon, whereas gastroduodenoscopy indicated mucosal lesions in the oesophagus. Haematoxylin and eosin (HE) staining and immunohistochemical analysis (IHC) revealed positive expression of α-methylacyl-CoA racemase (P504S) and androgen receptor (AR), confirming a diagnosis of oesophageal metastasis of prostate cancer. Subcutaneous endocrine therapy with goserelin (3.6 mg every 28 days) was initiated.
conclusionsOesophageal metastasis of prostate cancer is extremely rare and typically indicates advanced disease with a poor prognosis. The clinical manifestations are nonspecific and often lead to misdiagnosis. A definitive diagnosis relies on histopathology and immunohistochemical markers, such as PSA and P504S. Clinicians should maintain a high index of suspicion for metastatic prostate cancer in cases of unexplained oesophageal lesions. We hope that this case will increase clinicians' awareness of metastatic oesophageal cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.